Road Closure at 801 Broadway Parking Garage
Effective June 18, 2014 - Road closures will block regular access to our Broadway parking garage. Please allow more time for travel to your appointment.
Detour Route and more information.
News & Updates
Find A Specialist
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Dejan Budimirovic, M.D.
Kennedy Krieger Institute
716 N. Broadway
Baltimore, MD 21205
Phone: (443) 923-2634
Dr. Dejan Budimirovic (pronounced Day-ahn Boo-dee-meer-o-vich) is the medical director of the Fragile X Clinic at Kennedy Krieger Institute. He is also an attending physician at the Institute's Clinical Research Center and an assistant professor at Johns Hopkins University School of Medicine. Dr. Budimirovic is board certified by the American Board of Psychiatry and Neurology in adult, child, and adolescent psychiatry.
Dr. Dejan Budimirovic earned his undergraduate degree from a pre-medical nursing program and his medical degree from Belgrade University, where he graduated magna cum laude. He completed residencies at Belgrade, Harvard, and New York University School of Medicine.
Dr. Budimirovic's accomplishments are longstanding. As the top student in his medical school, he achieved dozens of awards and honors. One of his most notable honors was the extraordinary opportunity he was given to complete his medical internship with the University Hospitals in Belgrade. Following his internship, Dr. Budimirovic was hired by the University Clinical Center, Department of Psychiatry. He completed a two-year core general psychiatric training and post-graduate study program in biological psychiatry with outstanding grades.
After moving with his family to the United States in 1994, Dr. Budimirovic completed residencies in general psychiatry at the Harvard University School of Medicine and in child and adolescent psychiatry at the New York University School of Medicine. These trainings helped expand his experience and knowledge in clinical psychiatry and further stimulated his research initiatives, bringing out his capacity for collaborative work (i.e., critical care medicine and a project in pediatric hematology). During this time, Dr. Budimirovic was awarded a Certificate of Excellence for his therapeutic skills and professionalism by the faculty and staff in the Division of Child and Adolescent Psychiatry (NYU Child Study Center and Bellevue Hospital Center).
Dr. Budimirovic's commitment to his academic career is enduring. His first academic appointment at Yale University was as a full-time assistant professor. During his four-year tenure at Yale as an attending psychiatrist, Dr. Budimirovic served several hundred patients (primarily adolescents as well as general/geriatric patients), instructed dozens of psychiatry residents, and served as Principal Investigator on a research project funded by a private foundation. He also showed leadership skills as the co-director of the adolescent unit at Yale. Following his appointment at Yale, Dr. Budimirovic was recruited by Stony Brook University to serve as an attending child psychiatrist and medical director of the Children's Psychiatric Inpatient Unit at the Stony Brook University Hospital.
In November 2004, Dr. Budimirovic joined the faculty at Johns Hopkins as a full-time assistant professor and an attending pediatric psychiatrist at the Kennedy Krieger Institute. While managing an active clinical case load, he continued to pursue various research initiatives. With his involvement as a co-investigator on private foundation- and National Institutes of Health (NIH)-funded grants at Yale, Stony Brook, and Johns Hopkins Universities, Dr. Budimirovic has solidified his research foundation.
Since his arrival at the Institute, Dr. Budimirovic has contributed to the expansion of clinical activities at the Fragile X Clinic. In 2006, the clinic joined the Fragile X Clinic & Research Consortium (FXCRC). Beginning in 2008 and continuing to the present, the U.S. Centers for Disease Control and Prevention have supported the FXCRC through grants designed to increase the understanding of fragile X syndrome (FXS). The clinic's commitment to that cause has continued to-date, including further advancement of the progression of the targeted treatments of FXS. The clinic has been selected as the site for two multi-site clinical trials for which Dr. Budimirovic is the main co-investigator:
- The Phase III, pivotal clinical trial of STX209 (Arbaclofen) for the treatment of social withdrawal in adults, adolescents and children with FXS, sponsored by Seaside Therapeutics, Inc., is active, expanding, and will be followed by open-label extension of these studies
- The Phase II clinical trial of a mGluR5 antagonist (FRAGXIS NP 27936) for the treatment of social withdrawal in adults with FXS, sponsored by Hoffmann-La Roche Ltd.
Dr. Budimirovic has taught undergraduate students at the Johns Hopkins University Homewood Campus, a visiting medical student from Australia, and child psychiatry residents from the Johns Hopkins University School of Medicine. He also mentors a visiting scholar from Austria on a collaborative project.
Dr. Budimirovic is board certified by the American Board of Psychiatry and Neurology in adult, child, and adolescent psychiatry, and has been re-certified in child and adolescent psychiatry. He is an active member of the American Academy of Child and Adolescent Psychiatry, former member of the American Psychiatric Association for 14 years, and the American Medical Association. As medical director of the Fragile X Clinic, Dr. Budimirovic is also a member of the FXCRC.
Throughout the last six to seven years, Dr. Budimirovic has been an integral part of the Center for Genetic Disorders of Cognition & Behavior, Fragile X Research Program at Kennedy Krieger Institute. He has published several publications in journals with a solid impact factor. One of his publications is an original work on determinants of social deficits in individuals with FXS and autism spectrum disorder (ASD) . This original and ongoing work has been a foundation for publications and several applications submitted to the NIH and other funding agencies. His peers continued to acknowledge and cite his original work on the social withdrawal phenomena in FXS, which was recently replicated in a much larger sample of a multi-site study in which our clinic participated. By systematically applying a variety of advanced methods, Dr. Budimirovic's ongoing research activities continue to contribute to the field.
In addition his roles as co-investigator on a number of current research studies, Dr. Budimirovic is also Principal Investigator on three projects: Fragile X Clinical and Research Cooperative Consortium Registry and Repository (JHH IRB NA_00028362); Fragile X Clinic Pharmacological Database (JHH IRB N_00069920), which will establish a database at the Institute for the purpose of future research; and Early Signs of Fragile X Syndrome (JHH IRB N_00072204), a multisite projects which aims to identify early clinical signs of FXS for the purpose of facilitating an earlier genetic diagnosis of FXS.
Lastly, in an effort to raise awareness and funds for Fragile X-related research and clinical care, Dr. Budimirovic also actively participated in the ninth annual Fragile X Advocacy Day held at Capitol Hill.
- CLINICAL TRIAL: Children, ages 5-13 years, with fragile X syndrome
- CLINICAL TRIAL: Adolescents and Adults with fragile X syndrome, Ages 14 - 50
- CLINICAL TRIAL: Children, ages 7-17 years, with depression or anxiety
Budimirovic, D.B., & Kaufmann, W.E. (2011). What Can We Learn About Autism from Studying Fragile X Syndrome? Developmental Neuroscience, 33 (5), 379-394. DOI:10.1159/000330213
Kaufmann, W.E., Capone, G., Clarke, M., & Budimirovic, D.B. (2008). Autism in Genetic Intellectual Disability: Insights into Idiopathic Autism. In Zimmerman, A.W. (Ed.), Autism: Current Theories and Evidence (81-108). Totowa, NJ: The Humana Press Inc.
Coffee, B., Ikeda, M., Budimirovic, D.B., Hjelm, L.N., Kaufmann, W.E., & Warren, S.T. (2008). Mosaic FMR1 Deletion Causes Fragile X Syndrome and Can Lead to Molecular Misdiagnosis: A Case Report and Review of the Literature. American Journal of Medical Genetics Part A, 146A, 1358-1367. DOI 10.1002/ajmg.a.32261
Budimirovic, D.B., Bukelis, I., Cox, C., Gray, R., Tierney, E., & Kaufmann, W.E. (2006). Autism Spectrum Disorder in Fragile X Syndrome: Differential Contribution of Adaptive Socialization and Social Withdrawal. American Journal of Medical Genetics, 140A (17),1814-1826. DOI 10.1002/ajmg.a.31405
Budimirovic, D.B., & Kaufmann, W.E. (2008, October). Social Withdrawal in Fragile X Syndrome: Characterization by Factor Analysis. Poster presented at the American Academy of Child & Adolescent Psychiatry's 55th Annual Meeting, Chicago, IL.
Budimirovic, D.B., & Kaufmann, W.E. (2010, March). Sequential Factor and Cluster Analyzes Support Co-morbid Autism Spectrum Disorder plus Social Anxiety Phenotype in Fragile X Syndrome. Poster presented at the Anxiety Disorders Association of America Annual Meeting, Baltimore, MD.
Hernandez, N., Keen, L., Budimirovic, D.B., & Kaufmann, W.E. (2010, July). Structural Neuroimaging Correlates of Autism and Social Anxiety in Boys with Fragile X Syndrome. A Poster presentation at the 12th International FXS Conference, Detroit, MI.